Document is current

Article History

Received: 6 June 2024

Accepted: 16 July 2024

First Online: 7 August 2024

Declarations

:

: Andrew Blauvelt has served as a speaker (received honoraria) for Lilly and UCB; has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant, EcoR1, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lilly, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, DermBiont, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx; and owns stock in Lipidio and Oruka. Kilian Eyerich has received grants and personal fees from AbbVie; has received personal fees from Almirall, Bristol Myers Squibb, LEO Pharma, Lilly, Janssen, Novartis, UCB, and Sanofi; and has received grants from Lilly, LEO Pharma, Janssen, Novartis, and UCB. Alan D. Irvine has received personal fees as a consultant/speaker from AbbVie, Arena, Eli Lilly, LEO Pharma, Novartis, Pfizer, and Sanofi Regeneron. He has been an investigator for AbbVie and Regeneron/Sanofi. Marjolein de Bruin-Weller has served as a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Amgen, Aslan, Galderma, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi‐Genzyme, and UCB. Shawn G. Kwatra has served as an advisory board member/consultant for AbbVie, Amgen, Arcutis, Aslan, Cara, Castle Biosciences, Celldex, Galderma, Genzada, Incyte, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi. He has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. He is currently affiliated with the Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, and the Maryland Itch Center, University of Maryland School of Medicine, Baltimore, MD. Melinda Gooderham is or has been an investigator, adviser, and/or speaker for AbbVie, Akros, Amgen, AnaptysBio, Arcutis, Aristea, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Dermira, Dermavant, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, LEO, Lilly, Medimmune, Merck, Meiji, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Genzyme, Sun Pharma, UCB, and Ventyx. Brian Kim has served as a consultant for AbbVie, Almirall, Amagma, Argenx, AstraZeneca, Bellus Health, Blueprint Medicines, Boehringer Ingelheim Corporation, Bristol Myers Squibb, Cara Therapeutics, Daewoong Pharmaceutical, Guidepoint Global, Janssen Pharmaceuticals, Incyte Corporation, Kiniksa Pharmaceuticals, LectureLinx, LEO Pharma, Lilly, Maruho, Novartis, OM Pharma, Pfizer, Sanofi Genzyme, Shaperon, Third Rock Ventures, and Trevi Therapeutics; is a stockholder of RecensMedical and Locus Biosciences; serves on the scientific advisory boards for Abrax Japan, Granular Therapeutics, RecensMedical, National Eczema Association, Cell Reports Medicine, and Journal of Allergy and Clinical Immunology; and holds a patent for the use of JAK inhibitors for chronic pruritus. Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, and Andrew M. Platt are full-time employees of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents. Jonathan I. Silverberg has received honoraria as a consultant, advisory board member, and/or speaker for AbbVie, AObiome, Arcutis, Alamar, Amgen, Arena, Arcutis, Asana, ASLAN, Boehringer Ingelheim, BioMX, Biosion, Bodewell, Cara, Castle, Celgene, Connect, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, and Union. His institution has received grants from Galderma and Pfizer.

: The Independent Ethics Committee or Institutional Review Board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent before screening.